Nintedanib (Vargatef; Ofev explained)

Nintedanib at a glance

Nintedanib is a targeted medicine taken as capsules. Vargatef is the brand described in the cancer-treatment instructions used for this article. It is commonly prescribed alongside docetaxel, a separate chemotherapy medicine. Nintedanib itself is not conventional chemotherapy or checkpoint immunotherapy.

Ofev also contains nintedanib, but its instructions concern treatment of lung scarring rather than this cancer schedule. The doses, treatment calendar and some organ-function instructions differ. Do not change brands, copy another patient's dose or combine supplies without your oncology pharmacist checking the prescription.

The main practical concerns are diarrhoea, vomiting, liver changes and safe coordination with docetaxel. Other important problems can include bleeding, clots, serious bowel or kidney problems and impaired wound healing. Regular tests and early reporting help the team decide whether treatment can continue safely.

What nintedanib does

Nintedanib blocks several tyrosine kinases: proteins that transmit growth signals inside cells. Its targets include receptors for vascular endothelial, platelet-derived and fibroblast growth factors. These signals help build and maintain blood vessels around a tumour. Blocking them can interfere with the tumour's support system. This is called inhibition of angiogenesis, meaning new blood-vessel formation.

These pathways also matter in normal tissues. That is why a medicine directed at tumour growth can still affect wound repair, blood vessels and organs such as the liver and kidneys. The word targeted does not mean side effects are always mild.

The aim is to control cancer for as long as useful benefit and acceptable tolerability continue. Your team assesses symptoms, examination and scans together; side-effect severity does not measure benefit.

How the team decides whether it is suitable

Your oncologist considers the confirmed diagnosis and tissue findings, previous treatment, scan results, general fitness and applicable prescribing information. Nintedanib does not have a universal companion-diagnostic mutation test in the reviewed cancer label. Molecular tests may still matter when deciding among your treatment options.

Bleeding risk needs particular attention. Tell the team about coughing up blood, bleeding disorders, blood-thinning medicines or a recent stroke or heart attack. Some tumour locations or appearances on scans raise bleeding concerns. Active brain metastases (cancer deposits in the brain), recent substantial lung bleeding or a tumour involving major vessels may make this treatment unsuitable under the reviewed guidance. The specialist assesses these details.

Report liver or kidney disease, high blood pressure, an aneurysm, previous bowel perforation, abdominal surgery and any wound that has not healed. Vargatef must not be used if you are allergic to nintedanib or its ingredients, including soya lecithin, or if you have a peanut allergy. Safety and effectiveness in people under eighteen have not been established for Vargatef.

Moderate or severe liver impairment makes Vargatef treatment unsuitable under its prescribing recommendations. Mild liver impairment requires particular vigilance even though the cancer label does not routinely reduce the starting dose. Severe kidney impairment has not been adequately studied. Ofev has different instructions for mild liver impairment; do not apply those to your cancer prescription yourself.

Before treatment starts

Expect blood tests to check blood-cell counts, liver function, kidney function and relevant salts in the blood. The team records symptoms, weight, medicines and blood pressure. Urine testing may assess protein loss. Report diarrhoea or poor fluid intake before the first dose.

Have a clear written calendar showing the docetaxel day, nintedanib days, capsule strength and number per dose. The team should explain what to do if an infusion is delayed, because the capsule calendar may need changing too. Keep the hospital's urgent contact instructions accessible.

Ask for a plan for diarrhoea and nausea, including which medicines to take and when to call. If docetaxel is part of treatment, take its prescribed steroid premedication exactly as directed and report missed doses before the infusion. Those steroids belong to the partner treatment's safety plan; they are not a reason to take nintedanib on the infusion day.

Pregnancy testing is needed when relevant. Discuss contraception, breastfeeding and fertility before starting. Mention upcoming surgery or dental procedures so that treatment and healing can be planned together.

How to take nintedanib

Dose and treatment calendar

A usual Vargatef cancer dose is 200 mg twice daily, approximately twelve hours apart, on days 2–21 of a 21-day cycle. Docetaxel is given on day 1. Do not take Vargatef on the day docetaxel is administered. The usual 200 mg dose uses two 100 mg capsules each time. Your prescription may be lower because of side effects.

The team may interrupt treatment and then reduce each dose to 150 mg, and if necessary to 100 mg. A 150 mg dose is one 150 mg capsule. Check the strength whenever a new pack is supplied. Do not exceed your prescribed dose or make reductions yourself.

Nintedanib may continue after docetaxel stops, while it remains helpful and tolerable. In that situation it is usually taken every day, with the revised calendar confirmed by the team. Duration is individual.

Ofev's usual adult lung-disease dose is 150 mg twice daily, which is different from the starting cancer schedule above. This comparison explains why internet instructions may conflict; it is not an alternative dose to select for yourself.

Food, swallowing and handling

Take Vargatef with food if possible, during or immediately before or after a meal, and keep the timing consistent. Swallow capsules whole with water. Do not chew, open or crush them. Tell the pharmacist promptly if swallowing is difficult. The reviewed instructions do not provide a home-made liquid or feeding-tube preparation.

The European product information contains testing of intact capsules taken immediately with a small amount of apple sauce or chocolate pudding. This does not permit opening a capsule or leaving it soaking. Ask the pharmacist whether swallowing an intact capsule with soft food is appropriate for you.

Keep capsules in their original packaging, protected from moisture and out of children's reach. Vargatef storage instructions specify no higher than 25°C (77°F); ask the pharmacy about safe storage in hot weather or during travel. Do not use a broken capsule or damaged open blister. If capsule contents contact your skin, wash immediately with plenty of water. Return unused supplies through the pharmacy's disposal system.

Missed doses, vomiting and extra doses

If you miss a dose, skip it and take the next dose at the scheduled time. Do not take a double dose or add capsules to make up for it. If you vomit after taking nintedanib, do not take another dose; take the next at its usual time and report ongoing vomiting.

Contact the team promptly if several doses are missed, swallowing becomes impossible or your infusion date changes. If you accidentally take too much, contact the hospital immediately and have the pack available. Do not wait for symptoms or try to correct the error with a self-designed dosing break.

Monitoring and checking benefit

Liver tests are checked before treatment and at the beginning of each cycle while nintedanib is combined with docetaxel. If nintedanib continues alone, the Vargatef label recommends monthly liver tests, with extra testing when clinically needed. The team may monitor more closely in people with lower body weight, older age or other liver-risk factors.

Blood counts need particular attention during combination treatment: at the beginning of cycles and around the expected low point after chemotherapy, called the nadir. Your team sets the dates. Low white cells can increase infection risk, and platelets help blood clot. Tests may be needed even when you feel well.

Kidney function, blood pressure, weight, hydration and symptoms are reviewed. Electrolytes need checking if diarrhoea or vomiting is significant. Urine tests may identify protein leakage. Heart tests depend on your history and symptoms; a universal schedule of heart scans or electrocardiograms is not specified for every Vargatef patient.

Scans and clinical assessment show whether treatment is helping. A pause or reduction may allow recovery from toxicity without automatically ending the treatment option. Some serious complications, however, require permanent stopping. Restart only when the oncology team confirms it is appropriate.

Common side effects and practical care

Diarrhoea and dehydration

Diarrhoea is a particularly important nintedanib effect. Start the prescribed anti-diarrhoeal plan at the first signs and contact the team early. Keep a record of stool frequency, watery stools, pain, fever and blood. Drink fluids according to your care plan; oral rehydration drinks may be helpful when advised. People with fluid restrictions need individual guidance.

Call urgently if diarrhoea is frequent, occurs at night, causes cramping, is not responding to the prescribed medicine or comes with dizziness or reduced urine. Blood in stools or severe abdominal pain needs assessment for causes beyond uncomplicated diarrhoea. Do not wait for a week because a prescribing table uses that duration for a clinician's dose-reduction decision. Early reporting is safer.

Dehydration and loss of salts can affect the kidneys and heart. The team may arrange blood tests, intravenous fluids, a treatment pause or a lower dose. Do not exceed the prescribed anti-diarrhoeal dose.

Nausea, appetite and abdominal discomfort

Take anti-sickness medicine as prescribed. Smaller meals and regular sips may be easier than a large meal. Report repeated vomiting, persistent pain, difficulty drinking or continuing weight loss. A dietitian can help you maintain intake without adding unnecessary food restrictions.

Mild indigestion and serious bowel problems cannot always be distinguished at home. New severe or worsening pain, a swollen or rigid abdomen, fever or blood should not be managed simply by changing food or taking painkillers.

Mouth, skin, hair and nerve changes

Mouth soreness, rash and itching can occur during treatment. Use gentle mouth care and a soft toothbrush. Seek help if ulcers or mouth pain interfere with drinking. For dry skin, a fragrance-free moisturiser may help; report an extensive, painful or rapidly worsening rash.

Hair loss and tingling or numbness in hands and feet are also reported in the treatment setting, with docetaxel an important contributor. Tell the team early if numbness affects walking, fastening buttons or handling hot objects. Do not assume symptoms must become severe before a dose can be adjusted. Hair changes vary; ask about practical support rather than assuming nintedanib alone predicts how much hair you will lose.

Fatigue can have several causes. Balance activity with rest and report a marked change, especially with breathlessness, fever or dizziness.

Important serious side effects

Liver injury

Blood tests can show liver irritation before symptoms appear. More serious drug-induced liver injury, including fatal cases, has been reported. Call urgently for yellow eyes or skin, dark urine, pain on the right side of the upper abdomen, unusual sleepiness or unexplained bruising. The team may hold treatment, investigate other causes and reduce or permanently stop it.

Do not restart because jaundice looks better or because a previous blood result was normal. The decision depends on the pattern and recovery of several liver measurements.

Infection and low blood counts

Adding nintedanib to docetaxel can increase severe neutropenia, meaning a low level of infection-fighting white cells. Fever with neutropenia and sepsis, a dangerous reaction to infection, can be life-threatening. Symptoms include fever, shaking chills, cough, painful urination or feeling suddenly unwell. Serious infection can occur without a high temperature.

Follow the hospital's urgent fever instructions and do not mask symptoms with repeated fever medicines before getting advice. Preventive medicines or injections to support white cells are individual decisions, not a standard requirement for every person taking nintedanib.

Bleeding, clots and blood-vessel problems

Nosebleeds may be mild, but serious bleeding can involve the lungs, bowel or brain. Report unusual bruising or bleeding promptly. Coughing up more than a small streak of blood, vomiting blood, black stools with weakness, uncontrolled bleeding or collapse needs emergency assessment. Blood-thinning medicines require a carefully monitored plan.

A painful swollen leg or arm can signal a clot and needs urgent assessment. Sudden breathlessness, chest pain, coughing blood or collapse may indicate a clot in the lungs. Sudden facial droop, one-sided weakness or difficulty speaking may indicate a stroke. Get emergency help. Life-threatening venous clots require stopping Vargatef under the prescribing guidance.

High blood pressure can occur. An aneurysm is a bulge in an artery; dissection is a tear in its wall. These have been reported with medicines affecting this growth-factor pathway. Sudden severe chest, back or abdominal pain, especially with sweating or collapse, is an emergency.

Bowel perforation, bowel ischaemia and pancreatitis

A perforation is a hole in the wall of the digestive tract. Ischaemic colitis is bowel inflammation caused by inadequate blood flow. Both can be serious, and some reported cases have been fatal. Seek emergency help for severe persistent abdominal pain, marked swelling, fever or bleeding, particularly if you feel faint or very unwell.

Perforation requires permanent discontinuation. Ischaemic colitis requires stopping; an exceptional restart is considered only after complete recovery and specialist reassessment. Inflammation of the pancreas has also been reported and can cause severe upper abdominal pain, sometimes extending to the back, with vomiting. Do not attempt to identify the cause yourself.

Kidney problems and protein loss

Kidney impairment or failure and heavy protein loss in urine have been reported. Protein loss may cause foamy urine or swelling around the eyes, feet or ankles. Report these changes, blood in urine or passing much less urine. Blood and urine tests help distinguish dehydration from other kidney injury. A treatment interruption may be necessary.

Brain symptoms and wound healing

Posterior reversible encephalopathy syndrome, or PRES, is a serious brain condition that may cause headache, visual changes, confusion or seizures. Despite the word reversible, recovery is not guaranteed. Get emergency help for seizures, severe confusion or sudden neurological or visual symptoms. Suspected PRES requires discontinuing nintedanib and urgent assessment, usually including brain imaging.

Nintedanib may interfere with wound healing. Inform the team before an operation or invasive dental treatment. Vargatef should not be started until at least four weeks after major surgery, and healing must also be adequate. A treatment break before surgery and the restart date require the surgeon and oncologist's plan; four weeks is not a universal pre-operation stopping interval. Report wounds that open, leak or appear infected.

Other medicines, supplements and vaccinations

Nintedanib is affected by a drug transporter called P-glycoprotein, which helps move medicines across cells. Some medicines can increase its level, while others lower it. Examples needing review include ketoconazole, erythromycin, rifampicin, carbamazepine, phenytoin and St John's wort. Do not start or stop an antibiotic, seizure medicine or supplement without checking. Taking them a few hours apart may not resolve an interaction.

Tell the team about anticoagulants, aspirin, anti-inflammatory painkillers and steroids. Some increase bleeding or bowel-related concerns. Prescribed anticoagulation is not automatically forbidden, but it needs individual assessment; warfarin may require closer clotting tests. Docetaxel has its own interaction rules, so the whole prescription must be checked.

Check vaccination plans with oncology. Live vaccines may be unsuitable during immune suppression, particularly with chemotherapy. Non-live vaccines may be appropriate, although protection can be reduced. The time to resume live vaccines is individual; do not assume a fixed waiting period applies to every nintedanib patient.

Everyday life during treatment

Use alarms or a medicine diary for morning and evening capsules, and mark the docetaxel day clearly. Arrange repeat supplies before travel. Carry the medicine in its original packaging and keep appointments for blood tests even when you feel well.

Choose manageable meals and discuss persistent appetite problems. Avoid excess alcohol and ask what is appropriate given liver tests and other medicines. Smoking cessation support is worthwhile; smoking has been associated with lower nintedanib exposure in Ofev studies. Do not compensate by increasing your dose.

Avoid driving if dizzy, unwell, very tired or affected by vision or concentration problems. Arrange transport for chemotherapy visits if premedication or the infusion affects alertness. Tell dentists and other clinicians about both medicines before procedures.

Ask about intimacy, contraception and comfort. Support for anxiety, hair changes or repeated appointments is part of cancer care.

Fertility, contraception, pregnancy and breastfeeding

Nintedanib can harm a developing baby. Females who could become pregnant need highly effective contraception from the start of treatment, throughout treatment and for at least three months after the final nintedanib dose. Pregnancy testing is needed before treatment. Report a suspected pregnancy promptly.

Nintedanib does not meaningfully reduce exposure to the studied contraceptive-pill hormones, but vomiting or diarrhoea can reduce absorption of an oral contraceptive. If this happens, contact the team about an alternative highly effective method and interim precautions. Do not assume the pill still provides reliable protection.

Docetaxel adds separate requirements. US Taxotere information specifies contraception for females for six months after the last dose and for males with partners who could become pregnant for three months. European Taxotere information specifies two months for females and four months for males. Your team must set a plan meeting every applicable medicine's requirement, counted from its own last dose. Do not shorten precautions because nintedanib has a three-month interval.

The reviewed nintedanib labels do not give a fixed male contraception interval, and human fertility effects remain uncertain. Animal information raises concern about female fertility in the Ofev label; docetaxel can affect male fertility. Discuss preservation options before treatment if future parenthood matters to you.

Do not breastfeed during nintedanib treatment. Its labels do not specify one universal time to restart afterwards. Docetaxel also restricts breastfeeding, with the US label specifying one week after its final dose. That interval does not override continuing nintedanib treatment or replace an individual plan covering both drugs.

After treatment finishes

Keep planned blood tests and report persistent diarrhoea, abnormal bleeding, jaundice, swelling or reduced urine. Nerve symptoms related to the treatment combination can take time to improve and sometimes persist. Tell the team about ongoing difficulties rather than assuming that stopping treatment means no further help is possible.

Continue contraception for the full agreed intervals. Ask before breastfeeding, vaccination or an operation. Return unused capsules through the pharmacy and keep a record of your last doses and any serious reactions. If nintedanib alone is continuing after chemotherapy, this is still active treatment with its own monitoring and precautions.

Frequently asked questions